Puma Biotechnology Inc. (PBYI)

52.45
1.00 1.90
NASDAQ : Health Technology
Prev Close 51.45
Open 51.35
Day Low/High 51.25 / 53.65
52 Wk Low/High 50.50 / 136.90
Volume 132.19K
Avg Volume 794.10K
Exchange NASDAQ
Shares Outstanding 37.81M
Market Cap 1.98B
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology And Pint Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Latin America

Puma Biotechnology And Pint Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Latin America

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.

NCCN Guidelines For Central Nervous System Cancers Include NERLYNX® (neratinib) In Combination With Capecitabine Or Paclitaxel As Treatment Options For Patients With Breast Cancer Brain Metastases

NCCN Guidelines For Central Nervous System Cancers Include NERLYNX® (neratinib) In Combination With Capecitabine Or Paclitaxel As Treatment Options For Patients With Breast Cancer Brain Metastases

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that NERLYNX® (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network...

Robbins Geller Rudman & Dowd LLP Announces Pending Class Action In The Puma Biotechnology, Inc. Litigation

Robbins Geller Rudman & Dowd LLP Announces Pending Class Action In The Puma Biotechnology, Inc. Litigation

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc.

Home Depot, Vale, Bank of America: 'Mad Money' Lightning Round

Home Depot, Vale, Bank of America: 'Mad Money' Lightning Round

Jim Cramer focuses on Home Depot, Vale, Bank of America, Kraft Heinz, Dominion Energy, Lululemon Athletica, StitchFix, Duke Energy and more.

The Right Stuff: Cramer's 'Mad Money' Recap (Thursday 3/8/18)

The Right Stuff: Cramer's 'Mad Money' Recap (Thursday 3/8/18)

Jim Cramer says that on Thursday we saw the right stocks rally, even if we didn't see it in the averages. This market had breadth.

Puma Biotechnology To Present At Cowen's Annual Healthcare Conference

Puma Biotechnology To Present At Cowen's Annual Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2017 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017.

Puma Biotechnology Receives Results Of CHMP Formal Decision For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Receives Results Of CHMP Formal Decision For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion, recommending the refusal of the...

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an...

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company's ongoing SUMMIT Phase II 'basket' clinical trial of PB272 (neratinib) in patients with tumors harboring...

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison...

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on January 16, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of an inducement stock option to...

Puma Biotechnology Announces Results Of CHMP Oral Explanation For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Results Of CHMP Oral Explanation For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a negative trend vote after meeting with the Company...

Puma Biotechnology Added To NASDAQ Biotechnology Index

Puma Biotechnology Added To NASDAQ Biotechnology Index

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI's annual re-ranking of biotechnology and pharmaceutical...

Puma Biotechnology Announces Meeting Of Scientific Advisory Group On Oncology In Europe To Review Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Meeting Of Scientific Advisory Group On Oncology In Europe To Review Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the European Medicines Agency (EMA) has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical...

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

Jim Cramer spotlights Under Armour, Tractor Supply, Enbridge, Casey's General Stores and Puma Biotechnology.

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.

Daiichi Sankyo And Puma Biotechnology Announce Research Collaboration With Major Cancer Center In HER2-Mutated Cancer

Daiichi Sankyo And Puma Biotechnology Announce Research Collaboration With Major Cancer Center In HER2-Mutated Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc.

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent (EP 2416774), which were being opposed by Hexal AG.

CONTROL Trial At SABCS

CONTROL Trial At SABCS

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that...

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Specialised Therapeutics Asia, an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East...

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma's drug neratinib in patients with early stage...

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30, 2017.

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has entered into a loan agreement with Silicon Valley Bank, the bank of the world's most innovative companies and their investors, and Oxford Finance, a...